Navigation Links
Cylex(TM) Elects Richard A. Sandberg as Independent Director
Date:3/10/2010

COLUMBIA, Md., March 10 /PRNewswire/ -- Cylex announced today the election of Richard A. ("Dick") Sandberg, founder of DIANON Systems, as an independent director on the Company's board.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100112/NE34738LOGO )

Brad L. Stewart, chairman of the board and CEO of Cylex states, "Dick's leadership and achievements in diagnostics are a perfect match for Cylex.  With the guidance of Dick and the board, we will continue to build a valuable diagnostics platform to monitor patients' immune status."

Mr. Sandberg adds, "Cylex's technology, ImmuKnow®, creates an entirely new tool to help identify transplant patients at risk of infection due to over-immunosuppression, with promising potential in other areas outside of transplant."

"Dick brings with him deep operational expertise in building and running international diagnostics businesses.  This is a landmark step in Cylex's vision to become a global player in immunity-related diagnostics," said Stephen Bloch, MD, General Partner with Canaan Partners and a director of Cylex.

Greg Shearer, founder and principal of Channel Medical Partners stated, "Dick's extensive background and recognized contributions to the diagnostics field make him the ideal candidate to build on Cylex's growth.  In particular, his close connection to clinical diagnostics and his wealth of knowledge, skill and experience will be important assets to the board."

With the addition of Mr. Sandberg to the board, Tracy Marshbanks, PhD, Managing Director of First Analysis, will assume a role as an observer to Cylex's board.

Mr. Stewart affirmed, "We are extremely appreciative of Dr. Marshbanks' service on the board during the past two years and equally grateful to him for agreeing to remain as a board observer.  Cylex will continue to benefit from Dr. Marshbanks' experience in the life sciences industry."

About Richard A. ("Dick") Sandberg

An experienced and engaged executive officer, Mr. Sandberg works to launch and develop new medical diagnostic companies.  His record of success includes DIANON Systems Inc., where he was founder, chairman, CEO and chief financial officer.  The publicly traded oncology marketing and database company provide anatomic and clinical pathology services, patient information and business solutions to physicians. Mr. Sandberg also served as chairman and CFO of Lifecodes Corporation, a privately-held DNA testing technology firm; CFO and board member of Matritech Inc. (AMEX;MZT), a publicly-traded biotechnology company specializing in proteomic diagnostic products; CFO and board member of Critical Diagnostics Inc., a privately-held cardiac diagnostic company commercializing new technology licensed from the Brigham and Women's Hospital, Boston; and is the board chairman of Oxford Immunotec Ltd., a privately-held diagnostic company focusing on tuberculosis.

About Cylex, Inc.

Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit www.cylex.net.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression.  Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit www.cylex.net.

About Canaan Partners

Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies.  Founded in 1987, the firm has raised eight funds and completed more than 77 acquisitions and 52 IPOs.  With $3 billion under management and a worldwide footprint, the firm's healthcare team is committed to catalyzing the growth of biopharmaceutical, medical device and diagnostics companies that are revolutionizing the practice of medicine.  Among its successes are BiPar Sciences, a biopharmaceutical company pioneering novel tumor-selective therapies to address urgent unmet needs of cancer patients; Cerexa Inc., one of the largest biotech acquisitions of 2007; DexCom Inc., the largest diagnostic IPO of 2005; and Amicus Therapeutics, a pioneer of next-generation oral therapies for the management of human genetic diseases. Other Canaan healthcare investments include AdvancedBioHealing, Calibra Medical, Chimerix, Inc., Liquidia Technologies, Transcend Medical and VaxInnate.  Canaan has offices in California, Connecticut, India and Israel.  For more information, visit www.canaan.com.

About Channel Medical Partners

Channel Medical Partners is a leading emerging growth investor in medical technology companies. This stage of financing has historically represented a narrow channel or bottleneck for emerging growth companies – the point in their development between the substantial capital provided by earlier stage venture capital investors and that provided by institutions focused primarily on public companies. The firm has a demonstrated record of success in not only providing capital, but in enabling and ensuring the commercial success of its portfolio companies. The principals at Channel believe that the commercialization process has emerged as a critical activity at venture-backed companies and that their success has, in part, been driven by this trend.  For more information, visit www.chanmed.com.

SOURCE Cylex, Inc.

Back to top

RELATED LINKS
http://www.cylex.net

'/>"/>

SOURCE Cylex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
2. ProUroCare Medical Elects Two New Directors
3. Federal Aviation Administration Selects Partners For Nationwide AED Program
4. Home Diagnostics Selects Parago to Deliver Consumer Incentives Focused on Best Customer Experience
5. Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors
6. Customer Elects to Forego Commercial Production of Product
7. Pfizer Selects ChemAxons Markush Platform
8. Northeast Alabama Regional Medical Center Selects Allscripts to Automate Emergency Department and Connect Caregivers
9. Intermountain Healthcare Selects Craneware Revenue Integrity Solutions
10. Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications
11. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... PROVIDENCE, N.J. , April 26, 2017 Phoenix ... announce its fifteenth year of fulfilling its mission of transforming ... industry is highly scrutinized, Phoenix,s innovative ... the healthcare community about the latest advances in science and ... Phoenix was founded in 2002 by ...
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced ... test throughout the Northeast U.S. , GlycoMark is the only clinically available ... test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often ...
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... 27, 2017 , ... Today, Jefferson Health in Philadelphia and ... an agreement to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. ... Korman Family Foundation. The collaboration leverages the strengths of each organization and will ...
Breaking Medicine News(10 mins):